Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Larimar Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Larimar Therapeutics, Inc.’s stock price such as:

• Larimar Therapeutics, Inc.’s current stock price and volume
• Why Larimar Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for LRMR from analysts
• LRMR’s stock price momentum as measured by its relative strength

About Larimar Therapeutics, Inc. (LRMR)

Before we jump into Larimar Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Want to learn more about Larimar Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Larimar Therapeutics, Inc..

Larimar Therapeutics, Inc.’s Stock Price as of Market Close

As of February 25, 2026, 2:17 PM, CST, Larimar Therapeutics, Inc.’s stock price was $6.149.

Larimar Therapeutics, Inc. is up 66.63% from its previous closing price of $3.690.

During the last market session, Larimar Therapeutics, Inc.’s stock traded between $3.650 and $6.420. Currently, there are approximately 78.32 million shares outstanding for Larimar Therapeutics, Inc..

Larimar Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Larimar Therapeutics, Inc. Stock Price History

Larimar Therapeutics, Inc.’s (LRMR) price is currently up 73.69% so far this month.

During the month of February, Larimar Therapeutics, Inc.’s stock price has reached a high of $6.420 and a low of $2.715.

Over the last year, Larimar Therapeutics, Inc. has hit prices as high as $5.370 and as low as $1.610. Year to date, Larimar Therapeutics, Inc.’s stock is up 61.38%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Larimar Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of February 24, 2026, there were 0 analysts who downgraded Larimar Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Larimar Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Larimar Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Larimar Therapeutics, Inc. (LRMR) by visiting AAII Stock Evaluator.

Relative Price Strength of Larimar Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of February 24, 2026, Larimar Therapeutics, Inc. has a weighted four-quarter relative price strength of 7.01%, which translates to a Momentum Score of 69 and is considered to be Strong.

Want to learn more about how Larimar Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Larimar Therapeutics, Inc. Stock Price: Bottom Line

As of February 25, 2026, Larimar Therapeutics, Inc.’s stock price is $6.149, which is up 66.63% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Larimar Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.